Schalop Lee Troy 4

What Happened
Schalop Lee Troy, a director of Lantern Pharma (LTRN), purchased 48,544 common shares in a transaction on May 12, 2026 at $2.06 per share, for a total reported purchase price of $100,001. The Form 4 also reports a derivative entry for 48,544 securities at $0.00; per the filing footnote, these are warrants issued in the company’s offering that closed May 14, 2026. The purchase is a direct buy of common stock (a purchase, which investors often view as a positive signal), while the derivative entry reflects related warrants.

Key Details

• Transaction date: May 12, 2026; reported on Form 4 filed May 14, 2026 (filed within the normal reporting window).
• Shares purchased: 48,544 shares at $2.06 each; total cash paid: $100,001.
• Derivative reported: 48,544 securities at $0.00 (per footnote, warrants issued in the offering). Warrants are exercisable beginning November 14, 2026.
• Shares owned after transaction: not specified in the disclosed summary of this filing.
• Footnote: F1 — securities were acquired in the issuer’s offering that closed May 14, 2026; warrants exercisable starting Nov 14, 2026.

Context
This filing shows a straightforward open-market or offering purchase of common shares plus related warrants from the same offering. Purchases by directors are often noted by investors as potentially informative, but filings do not state the insider’s motive. The derivative line reflects issuance of warrants (not an exercised option or a public sale); the warrants have a future exercise date per the footnote.